☆ 4.3 Article

Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk

CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial

Reno Eufemon Cereno et al.

Summary: This study evaluated the effect of sacrificing target coverage to prioritize organs-at-risk during stereotactic ablative radiotherapy (SABR) planning on dosimetry, local recurrence, and progression-free survival. The results showed that despite sacrificing target coverage, there was no negative impact on local recurrence and progression-free survival. Therefore, optimizing organ-at-risk constraints in SABR planning for oligometastases is a safe approach.

RADIOTHERAPY AND ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Survival After Adrenalectomy for Metastatic Lung Cancer

Lauren N. Krumeich et al.

Summary: The aim of this study was to evaluate the clinical benefit of adrenal metastasectomy for all lung cancer subtypes. The results showed that patients undergoing adrenal metastasectomy had longer disease-free survival and overall survival. Adrenal metastasectomy should be considered for isolated adrenal metastases of non-small cell lung cancer, while small cell histology and extra-adrenal metastases are relative contraindications.

ANNALS OF SURGICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial

Matthew Van Oirschot et al.

Summary: This study assessed the association between target coverage compromise and patient outcomes in SABR treatment for oligometastases. The results showed that for some lesions, a reduction in dose or target coverage was necessary to meet organ at risk constraints. However, target coverage was not significantly associated with survival outcomes or lesional control.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Article Oncology

Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy A Pooled Analysis of Trials in the US Food and Drug Administration Database

Mitchell S. Anscher et al.

Summary: This study found that receiving RT within 90 days prior to starting ICIs did not increase the risk of serious adverse events. Therefore, it seems safe to administer ICIs within 90 days of receiving RT. Further prospective trials are needed to confirm these findings.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period

Claire van Vliet et al.

Summary: This study investigated treatment patterns for adrenal metastases using surgery or SABR at a single institution. The number of patients undergoing SABR doubled since 2016, while the numbers undergoing surgery remained unchanged. Both treatments showed low rates of acute toxicity and similar survival outcomes.

RADIOTHERAPY AND ONCOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

eLocal Therapy for Oligometastatic Disease-Cart Before the Horse?

Puneeth Iyengar

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Article Oncology

Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy

Hanbo Chen et al.

Summary: This study shows that MR-guided daily-adaptive SABR can reduce gastric toxicity in patients with left adrenal tumors, while dose escalation may be considered for patients with right-sided lesions due to low predicted NTCP. Adaptation benefits were significantly associated with lesion laterality, with left-sided lesions benefiting more than right-sided lesions.

RADIOTHERAPY AND ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors

Priscilla K. Stumpf et al.

Summary: This study reviewed literature on SBRT for adrenal metastases published from 2008 to 2017, and developed treatment guidelines and a tumor control probability model based on the findings. The research recommended tumor doses greater than or equal to 116.4 Gy (α/β = 10 Gy) for achieving high LC rates, while further studies following unified reporting standards are needed for more robust prediction.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Oncology

Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients

William C. Chen et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

添加到收藏夹

Article Urology & Nephrology

Prognostic factors after adrenalectomy for adrenal metastasis

A. Goujon et al.

INTERNATIONAL UROLOGY AND NEPHROLOGY (2020)

添加到收藏夹

Article Oncology

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

Yolande Lievens et al.

RADIOTHERAPY AND ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

David A. Palma et al.

BMC CANCER (2019)

添加到收藏夹

Article Oncology

Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases

Miguel A. Palacios et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors

Maryellen R. M. Sun et al.

AMERICAN JOURNAL OF ROENTGENOLOGY (2016)

添加到收藏夹

Article Oncology

Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma

Shankar Siva et al.

FUTURE ONCOLOGY (2016)

添加到收藏夹

Editorial Material Oncology

Vertebral fractures - An underestimated side-effect in patients treated with radio(chemo)therapy

Karoline Pilz et al.

RADIOTHERAPY AND ONCOLOGY (2016)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.